|
1) Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002; 122: 1500-11
|
|
|
|
2) 田妻 進, 二村雄次, 税所宏光, 他. 胆石症診療ガイドライン作成をめぐって(第二報). 日本消化器病学会雑誌. 2008; 105: 95
|
|
|
|
|
3) Grünhage F, Lammert F. Gallstone disease. Pathogenesis of gallstones: A genetic perspective. Best Pract Res Clin Gastroenterol. 2006; 20: 997-1015
|
|
|
|
|
4) Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008; 14: 778-82
|
|
|
|
|
|
5) Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett. 2008; 582: 10-8
|
|
|
|
|
|
6) Wittenburg H, Lyons MA, Li R, et al. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. Gastroenterology. 2003; 125: 868-81
|
|
|
|
|
|
7) Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004; 10: 1352-8
|
|
|
|
|
|
8) Goodwin B, Watson MA, Kim H, et al. Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol Endocrinol. 2003; 17: 386-94
|
|
|
|
|
|
9) Jiang ZY, Parini P, Eggertsen G, et al. Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients. J Lipid Res. 2008; 49: 464-72
|
|
|
|
|
|
10) Uppal H, Zhai Y, Gangopadhyay A, et al. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology. 2008; 47: 1331-42
|
|
|
|
|
|
11) Davies JP, Levy B, Ioannou YA. Evidence for a Niemann-Pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics. 2000; 65: 137-45
|
|
|
|
|
|
12) Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007; 117: 1968-78
|
|
|
|
|
|
13) Wang HH, Portincasa P, Mendez-Sanchez N, et al. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology. 2008; 134: 2101-10
|
|
|
|
|
|
14) Tsai CJ, Leitzmann MF, Willett WC, et al. Statin use and the risk of cholecystectomy in women. Gastroenterology. 2009; 136: 1593-600
|
|
|
|
|
|
15) Tazuma S, Kajiyama G, Mizuno T, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol. 1998; 26: 287-91
|
|
|
|
|